Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 90-94

  Illa, Isabel ^a,d   Diaz Manera, Jordi ^a,d   Rojas Garcia, Ricard ^a,d   Pradas, Jesus ^a,d   Rey, Antonio ^c   Blesa, Rafael ^a,d   Juarez, Candido ^b   Gallardo, Eduard ^a,d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Hospital Terrassa   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

AChR antibodies; MuSK antibodies; Myasthenia Gravis treatment; Rituximab

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN G; MUSK ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; STATISTICS, NONPARAMETRIC;

EID: 51849141688     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.04.039     Document Type: Article

References (40)

1. Baek W.S., Bashey A., and Sheean G.L. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 78 (2007) 771
2. Bartoccioni E., Scuderi F., Minicuci G.M., Marino M., Ciaraffa F., and Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67 (2006) 505-507
3. Berger J.R. Progressive multifocal leukoencephalopathy. Curr. Neurol. Neurosci. Rep. 7 (2007) 461-469
4. Buckley C., and Vincent A. Autoimmune channelopathies. Nat. Clin. Pract. Neurol. 1 (2005) 22-33
5. Chambers S.A., and Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14 (2005) 210-214
6. Conti-Fine B.M., Milani M., and Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 (2006) 2843-2854
7. Deymeer F., Gungor-Tuncer O., Yilmaz V., Parman Y., Serdaroglu P., Ozdemir C., Vincent A., and Saruhan-Direskeneli G. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68 (2007) 609-611
8. Diaz-Manera J., Rojas-Garcia R., Gallardo E., Juarez C., Martinez-Domeno A., Martinez-Ramirez S., Dalmau J., Blesa R., and Illa I. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat. Clin. Pract. Neurol. 3 (2007) 405-410
9. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., Marino M., and Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 (2003) 2304-2311
10. Gajdos P., Chevret S., and Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst. Rev. 1 (2008) 1-25 (CD002277)
11. Gajra A., Vajpayee N., and Grethlein S.J. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am. J. Hematol. 77 (2004) 196-197
12. Hain B., Jordan K., Deschauer M., and Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 33 (2006) 575-580
13. Hart I.K., Sathasivam S., and Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst. Rev. 4 (2007) 1-46 (CD005224)
14. Hilton-Jones D. When the patient fails to respond to treatment: myasthenia gravis. Pract. Neurol. 7 (2007) 405-411
15. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
16. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J. Neurol. 252 Suppl 1 (2005) I14-I18
17. Illa I., Diaz-Manera J.A., Juarez C., Rojas-Garcia R., Molina-Porcel L., Aleu A., Pradas J., and Gallardo E. "Seronegative" myasthenia gravis and antiMuSK positive antibodies: description of Spanish series. Med. Clin. (Barc.) 125 (2005) 100-102
18. Jaretzki III A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., and Sanders D.B. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 (2000) 16-23
19. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 (2004) 484-505
20. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
21. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., and Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55 (2004) 580-584
22. Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin. Neurol. 23 (2003) 191-198
23. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol. 26 (2007) 5-10
24. Pescovitz M.D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 6 (2006) 859-866
25. Richman D.P., and Agius M.A. Treatment of autoimmune myasthenia gravis. Neurology 61 (2003) 1652-1661
26. Sanders D.B., El-Salem K., Massey J.M., McConville J., and Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60 (2003) 1978-1980
27. Saperstein D.S., and Barohn R.J. Management of myasthenia gravis. Semin. Neurol. 24 (2004) 41-48
28. Schneider-Gold C., Gajdos P., Toyka K.V., and Hohlfeld R.R. Corticosteroids for myasthenia gravis. Cochrane Database Syst. Rev. 2 (2005) 1-20 (CD002828)
29. Scuderi F., Marino M., Colonna L., Mannella F., Evoli A., Provenzano C., and Bartoccioni E. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab. Invest. 82 (2002) 1139-1146
30. Sieb J.P. Myasthenia gravis: emerging new therapy options. Curr. Opin. Pharmacol. 5 (2005) 303-307
31. Skeie G.O., Apostolski S., Evoli A., Gilhus N.E., Hart I.K., Harms L., Hilton-Jones D., Melms A., Verschuuren J., and Horge H.W. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 13 (2006) 691-699
32. Stickler D.E., Massey J.M., and Sanders D.B. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin. Neurophysiol. 116 (2005) 2065-2068
33. Taylor R.P., and Lindorfer M.A. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat. Clin. Pract. Rheumatol. 3 (2007) 86-95
34. Thakre M., Inshasi J., and Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J. Neurol. 254 (2007) 968-969
35. Tokunaga M., Fujii K., Saito K., Nakayamada S., Tsujimura S., Nawata M., and Tanaka Y. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44 (2005) 176-182
36. Vincent A., and Leite M.I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18 (2005) 519-525
37. Vincent A., Bowen J., Newsom-Davis J., and McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2 (2003) 99-106
38. Wylam M.E., Anderson P.M., Kuntz N.L., and Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J. Pediatr. 143 (2003) 674-677
39. Zaja F., Russo D., Fuga G., Perella G., and Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55 (2000) 1062-1063
40. Zhou L., McConville J., Chaudhry V., Adams R.N., Skolasky R.L., Vincent A., and Drachman D.B. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30 (2004) 55-60